Dr. rer. nat. Sarina Schwarz

Mein Forschungsschwerpunkt liegt im Bereich Krebsfrüherkennung und -prävention, wobei ich mich im Rahmen meiner Dissertation vor allem mit dem Darmkrebsscreening beschäftigt habe und diesem Thema auch weiterhin meine Aufmerksamkeit schenke. Dies beinhaltet Studien zur Wirksamkeit, Inanspruchnahme und Qualität von Koloskopien. Ich beschäftige mich aber auch intensiv mit der Prävention von anderen Krebserkrankungen, u.a. von Gebärmutterhalskrebs im Rahmen der HPV-Impfung. Meine jahrelange Erfahrung in der Auswertung von Versichertendaten bringe ich außerdem in Projekten im Bereich der Pharmakoepidemiologie ein.

ORCiD: 0000-0002-7926-2032

Ausgewählte BIPS-Veröffentlichungen

• Zeitschriftenartikel mit peer-review

• Hornschuch M, Schwarz S, Haug U. High utilization of colonoscopy and fecal occult blood testing for screening or diagnostic purposes in Germany: A longitudinal analysis. European Journal of Cancer Prevention. 2025; (Epub 2025 Feb 10).
  https://doi.org/10.1097/CEJ.0000000000000956
• Hornschuch M, Schwarz S, Haug U. Proportion and characteristics of screen-detected and non-screen-detected colorectal cancers in Germany. Acta Oncologica. 2024;63(1):924-931.
  https://doi.org/10.2340/1651-226X.2024.40234
• Schwarz S, Braitmaier M, Pox C, Kollhorst B, Didelez V, Haug U. 13-year colorectal cancer risk after lower-quality, higher-quality and no screening colonoscopy: A cohort study. Journal of Clinical Epidemiology. 2024;176:111571.
  https://doi.org/10.1016/j.jclinepi.2024.111571
• Reilev M, Jensen PB, Ranch LS, Egenberg A, Furu K, Gembert K, Hägg D, Haug U, Karlstad Ø, Reutfors J, Schäfer W, Schwarz S, Smits E, Holthuis E, Herings R, Trifirò G, Kirchmayer U, Cesare Rosa A, Belleudi V, Gini R, Støvring Henrik, Hallas J. Methodology of the brodalumab assessment of hazards: A multicentre observational safety (BRAHMS) study. BMJ Open. 2023;13:e066057.
  https://doi.org/10.1136/bmjopen-2022-066057
• Schwarz S, Hornschuch M, Pox C, Haug U. Colorectal cancer after screening colonoscopy: 10-year incidence by site and detection rate at first repeat colonoscopy. Clinical and Translational Gastroenterology. 2023;14(1):e00535.
  https://doi.org/10.14309/ctg.0000000000000535
• Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. International Journal of Cancer. 2023;152(8):1547-1555.
  https://doi.org/10.1002/ijc.34375
• Braitmaier M, Schwarz S, Kollhorst B, Senore C, Didelez V, Haug U. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: A prospective study among 55-69-year-olds. Journal of Clinical Epidemiology. 2022;149:118-126.
  https://doi.org/10.1016/j.jclinepi.2022.05.024
• Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery - An analysis of German claims data. BMC Cancer. 2022;22:130.
  https://doi.org/10.1186/s12885-022-09240-w
• Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. European Journal of Cancer Prevention. 2022;31(6):497-504.
  https://doi.org/10.1097/CEJ.0000000000000736
• Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
  https://doi.org/10.1016/j.canep.2020.101812
  https://repository.publisso.de/resource/frl:6425860
• Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. Future Oncology. 2021;17(18):2305-2313.
  https://doi.org/10.2217/fon-2020-1052
  https://repository.publisso.de/resource/frl:6428548
• Schwarz S, Schäfer W, Horenkamp-Sonntag D, Liebentraut J, Haug U. Follow-up of 3 million persons undergoing colonoscopy in Germany: Utilization of repeat colonoscopies and polypectomies within 10 years. Clinical and Translational Gastroenterology. 2021;12(1):e00279. (Erratum: Schwarz S, Schäfer W, Horenkamp-Sonntag D, Liebentraut J, Haug U. Clinical and Translational Gastroenterology. 2024;15(2):e00677. http://doi.org/10.14309/ctg.0000000000000677).
  https://doi.org/10.14309/ctg.0000000000000279

• Zeitschriftenartikel ohne peer-review

• Rischke N, Schwarz S, Haug U. Anwendung von Immuncheckpointinhibitoren in der Therapie von Lungenkrebs. Der Onkologe. 2021;27(11):1049-1057.
  https://doi.org/10.1007/s00761-021-01041-3

• Vorträge bei wissenschaftlichen Tagungen

• Braitmaier M, Schwarz S, Didelez V, Haug U. Target trial emulation avoids bias due to non-alignment at time-zero in studies on site-specific effectiveness of screening colonoscopy. 5th Conference of the Central European Network (CEN), 3-7 September 2023, Basel, Switzerland.
• Hornschuch M, Schwarz S, Haug U. Utilization of examinations for screening or diagnosis of colorectal cancer in Germany: A longitudinal analysis. 18. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2023, Würzburg.
• Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. 18. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2023, Würzburg.
• Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. 17. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-29. September 2022, Greifswald.
• Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. 17. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-29. September 2022, Greifswald.
• Braitmaier M, Schwarz S, Kollhorst B, Didelez V, Haug U. Effectiveness of screening colonoscopy in reducing colorectal cancer incidence - Emulated target trials from German claims data. 42nd Conference of the International Society for Clinical Biostatistics (ISCB), 18-22 July 2021, online presentation.
• Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. Viszeralmedizin, 13.-18. September 2021, Leipzig. (Abstract publiziert in: Zeitschrift für Gastroenterologie. 2021;59:e182)
• Schwarz S, Haug U. Colorectal cancer incidence within 10 years among one million persons undergoing screening colonoscopy: A claims data analysis. United European Gastroenterology (UEG) Week, 3-5 October 2021, online presentation. (Abstract published in: United European Gastroenterology Journal. 2021;9(S8):126)
• Haug U, Schwarz S. Studies on the effect of drugs on colorectal cancer incidence: Considerable risk of misleading results. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 16-17 September 2020, online presentation. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2020;29(S3):4673)

• Poster bei wissenschaftlichen Tagungen

• Braitmaier M, Schwarz S, Didelez V, Haug U. Time-zero violations cause bias in observational studies on screening colonoscopy. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
• Braitmaier M, Schwarz S, Didelez V, Haug U. Time-zero violations cause bias in observational studies on screening colonoscopy. United European Gastroenterology Week (UEG), 14-17 October 2023, Copenhagen, Denmark.
• Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
• Hornschuch M, Schwarz S, Haug U. Utilization of colorectal cancer screening and diagnostic colonoscopy in Germany: A longitudinal analysis. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
• Hornschuch M, Schwarz S, Haug U. Utilization of examinations for screening or diagnosis of colorectal cancer in Germany: A longitudinal analysis. United European Gastroenterology (UEG) Week, 14-17 October 2023, Copenhagen, Denmark.
• Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. Conference of the International Cancer Screening Network (ISCN), 21-23 June 2023, Turin, Italy.
• Schwarz S, Braitmaier M, Didelez V, Haug U. 13-year colorectal cancer risk: Comparing persons with a low- vs. high-quality screening colonoscopy vs. no screening colonoscopy. United European Gastroenterology (UEG) Week, 14-17 October 2023, Copenhagen, Denmark.
• Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. 3rd International Conference on Cancer Prevention, 26-27 October 2022, Heidelberg.
• Hornschuch M, Schwarz S, Haug U. Screen-detected vs. non-screen-detected colorectal cancer in Germany: A claims data analysis. United European Gastroenterology Week (UEG), 8-11 October 2022, Vienna, Austria.
• Reilev M, Bjødstrup Jensen P, Støvring H, Skov Ranch L, Gini R, Bartolini C, Trifirò G, Kirchmayer U, Cesare Rosa A, Belleudi V, Haug U, Schwarz S, Schäfer W, Herings R, Smits E, Overbeek J, Holthuis E, Furu K, Gembert K, Hägg D, Tari M, Lentile V, Ingrasciotta Y, Egenberg A, Hallas J, on behalf of the BRAHMS study group. BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study of a biological anti-psoriatic drug across six European countries. 38th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2022, Copenhagen, Denmark. (Abstract published in: Pharmacoepidemiology and Drug Safety. 2022;31(Suppl. 2):487)
• Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. United European Gastroenterology Week (UEG), 8-11 October 2022, Vienna, Austria.
• Schwarz S, Hornschuch M, Pox C, Haug U. Polyp detection rate and cumulative incidence of post-colonoscopy colorectal cancer in Germany. 3rd International Conference on Cancer Prevention, 26-27 October 2022, Heidelberg.
• Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. 16. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 20.-22. September 2021, Online-Poster.
• Hornschuch M, Schwarz S, Haug U. 10-year prevalence of diagnostic and screening colonoscopy use in Germany: A claims data analysis. United European Gastroenterology (UEG) Week, 3-5 October 2021, online poster. (Abstract published in: United European Gastroenterol Journal. 2021;9(S8):825)
• Schwarz S, Haug U. Colorectal cancer incidence within 10 years among one million persons undergoing screening colonoscopy: A claims data analysis. 16. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 20.-22. September 2021, Online-Poster.
• Schwarz S, Haug U. Utilization of repeat colonoscopies and polypectomies in Germany within 10 years: A claims data analysis based on more than 2 million index colonoscopies. 34. Deutscher Krebskongress, 19.-22. Februar 2020, Berlin.
• Schwarz S, Oppelt KA, Haug U. Using German claims data to characterize real-world treatment patterns in cancer patients - The example of crizotinib. 34. Deutscher Krebskongress, 19.-22. Februar 2020, Berlin.
• Schwarz S, Oppelt KA, Haug U. The potential of German claims data to characterize real-world treatment patterns in cancer patients - The example of crizotinib. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):221)

Weitere Publikationen finden Sie unter nachfolgendem Link:

• Weitere Publikationen

• WiSe 2024/2025: Seminar „Epidemiologie II“; Bachelorstudiengang Public Health/Gesundheitswissenschaft; Fachbereich 11: Human- und Gesundheitswissenschaften; Universität Bremen

• SoSe 2024: Seminar „Epidemiologie I“; Bachelorstudiengang Public Health/Gesundheitswissenschaft; Fachbereich 11: Human- und Gesundheitswissenschaften; Universität Bremen